GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Net Margin %

ENDV (Endonovo Therapeutics) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Endonovo Therapeutics's Net Income for the three months ended in Sep. 2024 was $-0.70 Mil. Endonovo Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Endonovo Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Endonovo Therapeutics's Net Margin % or its related term are showing as below:

ENDV' s Net Margin % Range Over the Past 10 Years
Min: -169150   Med: -4919.45   Max: 4946.43
Current: -38333.33


ENDV's Net Margin % is ranked worse than
95.7% of 1001 companies
in the Biotechnology industry
Industry Median: -132.46 vs ENDV: -38333.33

Endonovo Therapeutics Net Margin % Historical Data

The historical data trend for Endonovo Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Net Margin % Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,585.48 -238.55 -4,253.42 -13,685.19 4,946.43

Endonovo Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,586.67 -38,300.00 -26,716.67 - -

Competitive Comparison of Endonovo Therapeutics's Net Margin %

For the Biotechnology subindustry, Endonovo Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Net Margin % falls into.


;
;

Endonovo Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Endonovo Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=6.925/0.14
=4,946.43 %

Endonovo Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.697/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics  (OTCPK:ENDV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Endonovo Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics Headlines